DelveInsight’s ‘Psoriatic Arthritis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Psoriatic Arthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Psoriatic Arthritis pipeline domain.
Key Takeaways from the Psoriatic Arthritis Pipeline Report
Psoriatic Arthritis Overview
Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling.
Psoriatic arthritis is considered as seronegative spondyloarthropathies. The fact that it is Seronegative is that the blood tests negative for some factors that is present in rheumatoid arthritis.
Spondyloarthropathy describes a group of conditions that all share common characteristics. First, there is a presence of arthritis that affects the spine. Second, inflammation occurs in ligaments, tendons and sometimes in other organs such as the eye.
Request for a sample report to know more about rheumatoid arthritis treatment algorithm and diagnosis.
Psoriatic Arthritis Pipeline Analysis: Drug Profile
Risankizumab: Abbvie
Risankizumab is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases, including psoriasis.
Discover more about the emerging Psoriatic Arthritis drugs @ Psoriatic Arthritis Treatment Drugs
Psoriatic Arthritis Key Companies
Psoriatic Arthritis Pipeline Therapies
Psoriatic Arthritis Pipeline Therapeutics Assessment
Scope of the Psoriatic Arthritis Pipeline Report
Find out more about the Psoriatic Arthritis treatment options in development @ Psoriatic Arthritis Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Other Trending Reports:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Kritika Rehani
[email protected]
+1(919)321-6187
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/